Abstract library

27 results for "Avital".
#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Daneng Li
Authors: Li D, Imbesi G, Yen L, Kim H, ...
#2950 Hemicolectomy for Neuroendocrine Neoplasms of the Appendix - Is It Really Necessary?
Introduction: Appendical neuroendocrine neoplasms (ANENs) are rare. Limited data is available regarding prognosis and optimal treatment strategy in those tumors
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Orit Twito
Authors: Twito O, Klein N, Paran H, Avital S, ...
#2953 Temporal Trends in Incidence, Presentation and Work-Up of Neuroendocrine Neoplasms of the Appendix
Introduction: Although temporal trends in incidence and prognosis of neuroendocrine neoplasms have been described in the literature, data regarding trends in Appendiceal Neuroendocrine Neoplasms (ANENs) is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Orit Twito
Authors: Twito O, Klein N, Paran H, Avital S, ...
#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience
Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Ivana Puliafito
Keywords: mcc, avelumab, activity, safety
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#116 Transarterial chemoembolization (TACE) of liver metastasis from pancreatic well-differentiated endocrine carcinoma
Introduction: The behavior of liver metastasis from endocrine pancreatic carcinoma is eterogeneous, and several treatments have been proposed, but no single option is ideal.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD Vanessa Capitanio
Authors: Capitanio V, Papa M, Zerbi A, Vitali G, ...
#343 PCR Assessment of Carcinoid Lymph Node Metastasis CgA Transcript Outperforms Immunostaining, Tyramide Signal Amplification and H&E and Significantly Upstages Disease
Introduction: Accurate neuroendocrine tumor (NETs) staging is vital for determining therapeutic strategy. Sensitive techniques to facilitate identification of metastases (mets) are of critical clinical relevance.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kenney B, Kidd M, Modlin I, ...
#532 Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line
Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Rosario Pivonello
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Conference:
Category: Clinical
Presenting Author: Antongiulio Faggiano
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo